BPC-157

BPC-157, the “body protection compound” — what SGV’s teachers claim for healing and recovery, what the evidence actually is, and where the compound stands with regulators.

This hub is part of the SGV peptide library — start at the Peptides topic hub for the full map. Everything below is a roundup of what the teachers in this library say in their own videos, attributed to them. SGV draws no medical conclusions, and nothing here is dosing or sourcing guidance.

What the teachers say it is

BPC-157 is a fragment derived from a protein found in gastric juice — the “body protection compound.” Dr. William Seeds calls it one of the most versatile peptides in his practice in BPC-157: The Versatile Healing Peptide, claiming it supports tissue healing, new blood-vessel growth, inflammation modulation, gut protection and nerve protection. In BPC-157 and Recovery, he goes a level deeper: in his framing, the compound relates to the myofibroblast — the cell that lays down fibrous tissue — acting as a fail-safe against the excessive fibrosis he associates with tendinosis and chronic tendinitis.

The evidence reality check

Dr. Kyle Gillett’s basics episode, BPC-157 Peptide: Experts Explain What You Need to Know, is the library’s most cautious take: in his account, the popularity rests largely on animal tendon and muscle injury experiments plus limited, non-randomized human experience — not large controlled trials. He explains its proposed action through blood-vessel growth signaling, which in his view also explains the cautions he raises, and describes his own preference for short courses around connective-tissue injury or selected gut problems rather than indefinite use.

Nathalie Niddam makes the same caveat upfront in BPC157 — The One-Stop Peptide for Body, Brain & Gut: most published BPC-157 research is still animal work, and peptides remain research chemicals, not approved medicines. Her guest, Jean-Francois Tremblay, claims healing support across gut, tendons, organs, nerves and brain; note, as the episode itself flags, that the guest is affiliated with a peptide vendor.

The wider frame

Dr. Andrew Huberman places BPC-157 among the tissue-repair peptides in Benefits & Risks of Peptide Therapeutics for Physical & Mental Health, noting that reported benefits are largely anecdotal, and sorting the peptide world into prescription FDA-approved products, grey-market products of questionable safety and efficacy, and black-market products he warns are often contaminated. In Peptides: The Science, Uses & Safety, Dr. Abud Bakri likewise distinguishes FDA-approved options such as GLP-1 drugs from widely used compounds with far less human evidence, such as BPC-157. And in a clinical-recovery context, orthopedic surgeon Dr. Jason Snibbe discusses BPC-157 alongside TB-500 with Gary Brecka in Peptides for ACL Recovery, BPC-157 & TB-500, Robotic Surgery, & Prehab.

Where BPC-157 stands with regulators

Status as chronicled by RFK Team Report’s peptide coverage, as of October 18, 2026:

• September 29, 2023 — FDA placed BPC-157 and 18 other substances in Category 2 of its bulk drug substances list, blocking 503A compounding pharmacy use.
• April 15, 2026 — FDA removed 12 substances, including BPC-157, from Category 2 — a limbo, not an approval: removal did not make them lawfully compoundable.
• July 23–24, 2026 — the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend 6 of 7 newly nominated peptides for the 503A Bulks List; BPC-157 passed 8–6.
• October 14, 2026 — HHS/FDA submitted an “Interim Access Policy for Compounding Using Certain Peptides” for OMB review; its contents have not been disclosed.
• Bottom line, per that chronicle: as of October 18, 2026, BPC-157 is not FDA-approved and is not lawfully compoundable under 503A. The full timeline lives at rfkteamreport.com/peptides.

Go deeper by teacher

• Dr. William Seeds’ videos
• Dr. Kyle Gillett’s videos
• Nathalie Niddam’s videos
• Dr. Andrew Huberman’s videos

Related compound hubs: GLP-1 medications · TB-500 · GHK-Cu · All peptides